title: Quantitative detection of BCR-ABL fusion gene and its application in monitoring chronic myeloid leukemia treatment.
abstract: The BCR-ABL fusion gene in chromosome translocation, t (9; 22), and its product, p210BCR/ABL oncogenic tyrosine kinase, is the underlying molecular mechanism that leads to the development of CML. Quantitative detection of BCR-ABL fusion gene has become a reliable approach to diagnose and monitor CML. The aim of this study was to evaluate a Roche t (9; 22) kit in CML diagnosis, monitoring treatment responses, and identification of relapse. Using BCR-ABL fusion gene-expressing K562 cells, a series of standard samples were prepared and used to establish a curve for the calculation of BCR-ABL fusion gene expression in patient samples. Our results indicate that PCR detection system with aforementioned kit has good reproducibility. In addition, the relative concentration of BCR-ABL measured by PCR was in agreement with the patient's response to the Imatinib treatment and bone marrow morphology remission. Furthermore, we found that the relative concentration of BCR-ABL fusion gene increased 1-3 months before CML relapse was clinically and cytogenetically diagnosed, suggesting that the PCR-based BCR-ABL fusion gene detection with t (9; 22) kit is able to diagnose the recurrence of CML at least 1 month earlier than the classic cytogenetic analysis. In conclusion, detection of BCR-ABL fusion gene expression in CML using Roche t (9; 22) kit has great clinical value in the primary diagnosis, monitoring treatment responses, and identification of relapse in CML patients.
authors.affiliation: Department of Laboratory Medicine, West China Hospital, Sichuan University, 610041 Chengdu, Sichuan Province, People's Republic of China.
authors.forename: Xiaojun
authors.initials: X
authors.lastname: Lu
authors.forename: Xingbo
authors.initials: X
authors.lastname: Song
authors.forename: Yuanxin
authors.initials: Y
authors.lastname: Ye
authors.forename: Xianzhong
authors.initials: X
authors.lastname: Liu
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhou
authors.forename: Lei
authors.initials: L
authors.lastname: Zhang
authors.forename: Jun
authors.initials: J
authors.lastname: Wang
authors.forename: Binwu
authors.initials: B
authors.lastname: Ying
authors.forename: Lanlan
authors.initials: L
authors.lastname: Wang
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D015415:Biomarkers / Q000378:metabolism; D016026:Bone Marrow Transplantation; D016044:Fusion Proteins, bcr-abl / Q000235:genetics* / Q000378:metabolism*; D006801:Humans; D000068877:Imatinib Mesylate; D020014:K562 Cells; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000235:genetics* / Q000517:prevention & control* / Q000628:therapy*; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011933:Reagent Kits, Diagnostic; D012008:Recurrence; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D015415:Biomarkers; D010879:Piperazines; D011743:Pyrimidines; D011933:Reagent Kits, Diagnostic; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl